Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

BACKGROUND: cKIT kinase overexpression and gain-of-function mutations are the critical pathogenesis of gastrointestinal stromal tumors (GISTs). Although the multiple kinase inhibitors such as imatinib, sunitinib, and regorafenib have been approved for GISTs, the acquisition of polyclonal secondary r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feiyang, Zou, Fengming, Chen, Cheng, Yu, Kailin, Liu, Xiaochuan, Qi, Shuang, Wu, Jiaxin, Hu, Chen, Hu, Zhenquan, Liu, Juan, Liu, Xuesong, Wang, Li, Ge, Juan, Wang, Wenchao, Ren, Tao, Bai, Mingfeng, Cai, Yujiao, Xiao, Xudong, Qian, Feng, Tang, Jun, Liu, Qingsong, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535728/
https://www.ncbi.nlm.nih.gov/pubmed/31205508
http://dx.doi.org/10.1177/1758835919849757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535728/
https://www.ncbi.nlm.nih.gov/pubmed/31205508
http://dx.doi.org/10.1177/1758835919849757

Ejemplares similares